The pursuit of the RAS protein—a notorious driver of tumor growth once considered "undruggable"—is entering a more sophisticated phase. At the American Association of Cancer Research (AACR) annual meeting in San Diego, Revolution Medicines emerged as a central protagonist, presenting data that suggests its current lead candidate, daraxonrasib, is making significant inroads against advanced pancreatic cancer.
The clinical updates provided a dual-layered success story. Beyond showing efficacy as a monotherapy, daraxonrasib demonstrated promising results in both first-line and combination settings. For a disease as recalcitrant as pancreatic cancer, these markers of clinical progress represent a rare shift in momentum, moving the drug closer to becoming a cornerstone of targeted oncology.
However, the company is already looking past its current successes toward a more radical mechanism of action. Preclinical data presented for a new compound, RM-055, introduced what CEO Mark Goldsmith describes as a "novel class of catalytic inhibitors." While traditional targeted therapies focus on blocking the signaling pathways that fuel cancer, these new compounds are designed to molecularly switch the cancer-driving protein off entirely.
This shift from inhibition to deactivation marks a significant conceptual leap in drug design. If RM-055 can replicate its preclinical success in human trials, it would represent a transition from merely obstructing the machinery of a tumor to fundamentally disabling its core components. For Revolution Medicines, the goal is no longer just to slow the progression of RAS-driven cancers, but to master the molecular switches that govern them.
With reporting from STAT News.
Source · STAT News (Biotech)
